ADC Therapeutics SA
ADCTHealthcareNASDAQBiotechnology · Last scanned May 27, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 26
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. At a $446.4M market cap, ADC Therapeutics SA ranks as a small-cap company within healthcare. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Market Cap
$446.4M
Beta
1.84
P/E (TTM)
—
P/E (Fwd)
-2.36
EPS (TTM)
$-0.97
EPS (Fwd)
$-1.49
ROE
—
ROA
-22.7%
Cash
$231.0M
Total Debt
$436.3M
Free CF
-$74.9M
52W Change
27.9%
Annual Financials
Cash vs Debt
ADC Therapeutics SA carries $436.3M in total debt against $231.0M in cash reserves — debt is roughly 1.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$74.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been uneven over recent years, ranging from $209.9M to $81.4M.
ADC Therapeutics SA's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ADCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.